^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    onvansertib (PCM-075) (PLK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2022
    Title:

    3237 / 6 - Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance

    Published date:
    03/09/2022
    Excerpt:
    The combination of the PLK1 inhibitor onvansertib and the PARPi olaparib showed potent anti-tumor activity in olaparib-resistant BRAC1 mutant HGSOC PDX models.